Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Targovax ASA ( (GB:0RIS) ).
Circio Holding ASA has announced the conversion of convertible bonds into 1,655,811 new shares, increasing its share capital by NOK 993,486.60. This move, following previous conversions, will result in a total share capital of NOK 71,771,472.00, divided into 119,619,120 shares, reflecting the company’s strategic financial management and potential growth in the biotechnology sector.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in the development of circular RNA vector expression technology for advanced gene and cell therapies. Their proprietary circVec platform is designed to enhance RNA, DNA, and viral therapeutics, offering significant improvements in RNA stability and protein expression. The company is also advancing its immuno-oncology program, TG01, targeting RAS-mutated cancers through collaborations in Norway and the USA.
Average Trading Volume: 2,407,649
Current Market Cap: NOK135.8M
Learn more about 0RIS stock on TipRanks’ Stock Analysis page.